Science raises $400M Series D, reaching $3.5B valuation on retina chip
What's the deal? Science, the medical technology startup founded by former Neuralink president Max Hodak in 2021, has raised a $400 million Series D at a $3.5 billion valuation. Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 CapitalDealroom has a profile for this one. Try Dealroom →, Y Combinator, and PLC Neurotech backed the round.
What's the endgame? Science's first product, PRIMA, is a chip that helps people with age-related macular degeneration recover some vision. The device is approved in Europe and available in Germany, and the company is seeking US approval through the Food and Drug Administration's Humanitarian Device Exemption.
Why now? The raise comes months after a $230 million Series C. At TechCrunch Disrupt, Hodak said PRIMA is now being trialled for Stargardt's disease, a separate blindness-causing condition.
What's the big picture? Science's founding purpose is connecting directly to the brain through a bio-hybrid sensor built from cultured neurons and silicon. It is designing initial human trials with Yale neurosurgery professor Murat Günel, who said the device could offer "potential treatments" for Parkinson's disease and other brain conditions.
What could go wrong? PRIMA is a retinal implant, not a direct brain implant, and the company's brain-directed work remains investigational. The $3.5 billion valuation is a bet on scaling a medical device and advancing a pipeline that is not yet clinically established.
The signal: The round sits near the top of its class — above the 99th percentile for US health Series D rounds over the trailing 48 months. It also reflects a surge in neurotechnology funding: Neuralink announced a $650 million round, while Precision Neuroscience raised $250 million in September.
Read more: TechCrunch
Image credit: Science